臨床的相関値と13のC反応性タンパク質遺伝子ポリモルフィズムが,血清C反応性タンパク質レベルの個体間変動に与える貢献

Sekar Kathiresan¹, Martin G Larson, Ramachandran S Vasan

¹Framingham Heart Study, Framingham, MA 01702-5827, USA.

Circulation

|March 15, 2006

まとめ

臨床的要因は,C反応性タンパク質 (CRP) 変動の26%を説明し,一般的なCRP遺伝子変異がわずかに寄与している. CRPの遺伝的変異と心血管疾患のリスクを関連付けるため,さらなる研究が必要です.

科学分野:

遺伝学遺伝学とは
心血管疾患に関する研究
バイオマーカーバイオマーカー

背景:

血清のC反応性タンパク質 (CRP) は,心血管疾患に関連した遺伝的特徴です.
CRPの個体間変動性を理解することは,リスク予測に不可欠です.

研究の目的:

血清CRPレベルに影響を与える臨床的および遺伝的要因を調査する.
CRPレベルに関連するCRP遺伝子内の特定の遺伝的変異を特定する.

主な方法:

フレミングハム心臓研究に参加した3301人の血清CRPの分析.
CRPロクスの13の単核酸多形態体 (SNPs) の遺伝子型決定
臨床的共変数とSNPがCRPの変動に与える寄与を評価するための統計分析.

主要な成果:

12の臨床的共変数は,CRPの変動率の26%を説明し,BMIは15%を占めた.
13のCRP SNPのうち9つは,共変量調整後のCRPレベルと関連していました.
CRPプロモーターの三アルレ性SNP (rs3091244) は,CRP変異の1.4%を説明し,CRPレベルがより高いことと関連した小アルレがある.

結論:

臨床的変数は,CRPの個体間変動に大きく寄与する.
一般的なCRP遺伝子のSNPは,CRPレベルに控えめな影響を及ぼします.
CRPの遺伝子変異と心血管疾患のリスクとの関連性を調べるために,より大きな研究が推奨されます.

さらに関連する動画

07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

関連する概念動画

01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...

01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

関連する実験動画